Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ex Vivo Expansion and Hydrogel-Mediated In Vivo Delivery of Tissue Resident Memory T Cells for Immunotherapy

ABSTRACT: Tissue-resident memory (TRM) T cells preferentially reside in peripheral tissues, serving as key players in tumor immunity and immunotherapy. Currently, the lack of effective approaches for expanding TRM cells and delivering these cells in vivo hinder the exploration of TRM cell-mediated cancer immunotherapy. Here, we report a nanoparticle artificial antigen-presenting cell (nano-aAPC) ex vivo expansion approach and an in vivo delivery system for TRM cells. Using the nano-aAPC platform, we expanded functional antigen-specific murine and human TRM-like CD8+ T cells ex vivo. We also developed an injectable macroporous hyaluronic acid (HA) hydrogel for delivery of TRM-like cells. TRM-like cells delivered in the optimized HA hydrogel trigger robust local and systemic antitumor immunity and show synergistic effect with anti-PD1 treatment. Our findings suggest that nano-aAPC-induced TRM-like cells, coupled with a hydrogel delivery system, offer an efficient way to advance the understanding of TRM cells-mediated cancer therapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE267822 | GEO | 2024/06/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Ex Vivo Expansion and Hydrogel-Mediated In Vivo Delivery of Tissue Resident Memory T Cells for Immunotherapy

Project description:Ex Vivo Expansion and Hydrogel-Mediated In Vivo Delivery of Tissue Resident Memory T Cells for Immunotherapy

| PRJNA1113317 | ENA

Nano genome altas (NGA) of body wide tissue specific responses

Project description:Purpose: In order to detect the unpredictable risks of the cumulative nanoparticles infiltrated everywhere in the whole body after systematic administration Methods: By using RNA-seq, we systematically studied the transcriptomic response of multi-organs from mice and tissue specific (stem) cells to the hydroxyapatite (HA) nano-delivery system. Results: We show that HA could differentially influence gene expression, immune response, cell proliferation, stress, apoptosis, metabolic, ion transport activity, cell signaling and epigenetic activity across tissues and tissue specific (stem) cells.

2019-03-29 | GSE125742 | GEO

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma

Project description:Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immunotherapy sensitivities across 101 bone marrow (BM) samples from 70 MM patients using multiplexed immunofluorescence, automated microscopy and deep learning-based single-cell phenotyping. Combined with sample-matched genetics, proteotyping, and cytokine profiling, we map the molecular regulatory network of drug sensitivity, implicating the DNA-repair pathway and EYA3 expression in proteasome inhibitor sensitivity, and MHC class II expression in the response to Elotuzumab. Globally, ex vivo drug sensitivity associated with BM microenvironmental signatures reflecting treatment stage, clonality, and inflammation. Furthermore, ex vivo drug sensitivity significantly stratified clinical treatment responses, including to immunotherapy. Taken together, our study provides molecular and actionable insights into diverse treatment strategies for multiple myeloma patients.

2022-03-06 | MSV000088992 | MassIVE

AM in vivo and ex vivo RNAseq

Project description:AM in vivo and ex vivo RNAseq

| PRJNA799312 | ENA

Programmable envelopved delivery vehicels for human genome engineering in vivo

Project description:Viruses and virally-derived particles have the intrinsic capacity to deliver molecules to cells, but the difficulty of readily altering cell-type selectivity has hindered their use for therapeutic delivery. Here we show that cell surface marker recognition by antibody fragments displayed on membrane-derived particles encapsulating CRISPR-Cas9 protein and guide RNA can target genome editing tools to specific cells. These Cas9-packaging enveloped delivery vehicles (Cas9-EDVs), programmed with different displayed antibody fragments, confer genome editing in target cells over bystander cells in mixed cell populations both ex vivo and in vivo. This strategy enabled the generation of genome-edited chimeric antigen receptor (CAR) T cells in humanized mice, establishing a new programmable delivery modality with the potential for widespread therapeutic utility.

2023-06-30 | GSE235643 | GEO

Single cell CITE-seq and VDJ sequencing of CD8+ central memory blood T cells (TCM) and their in-vivo matured tissue-resident memory-like T cells (TRM)

Project description:The aim of the experiment was to understand the clonal relationship between CD8+ central memory blood T cells (TCM) and the in-vivo matured TCM tissue-resident memory-like T cells (TRM) on day 14. TCM were FACS sorted from human PBMCs (n=5). Half of the cells were processed on day 1 and half of the cells of each donor were matured into TRM with anti-CD3, IL-15 and TGF beta for 14 days. Both day 1 TCM and matured day 14 TRM-like cells were further processed using the 5´10X genomics workflow.

2023-06-12 | E-MTAB-12840 | biostudies-arrayexpress

Plasmodium knowlesi gene expression differs in ex vivo compared to in vitro blood-stage cultures

Project description:The purpose of this reasearch is to identify and evaluate the global gene expression of Plasmodium knowlesi blood-stage parasites and specifically compare the gene expression profiles of samples derived from ex vivo versus long-term in vitro cultures. For ex vivo samples, a rhesus monkey was infected with P. knowlesi to obtain ring iRBCs to establish a short-term culture to immediately collect ex vivo derived time points every 4 hours in the course of the parasite’s 24-hour life cycle. For in vivo samples, they were generated from the same clone in the ex vivo culture adapted to long-term in vitro culture and were collected every 4 hours in the course of the parasite's 24-hour life cycle. Two replicate experiments(Aa and Ha) were developed from in vitro cultures. Samples labeled with Cy5 were hybridized against a reference RNA pool labeled with Cy3, consisting of equal amounts of P. knowlesi RNA from each time point.

2015-06-08 | E-GEOD-62886 | biostudies-arrayexpress

RNA-seq of ex vivo primate cells

Project description:RNA-seq of ex vivo primate cells

| PRJEB43706 | ENA

In vivo dendritic cell reprogramming for cancer immunotherapy [organoid scRNA]

Project description:Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced tumor regressions, and established long-term systemic immunity in multiple mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy.

2024-09-05 | GSE255536 | GEO

In vivo dendritic cell reprogramming for cancer immunotherapy [T cell scRNA + TCR]

2024-09-05 | GSE255385 | GEO